Establishing Independent Targeted Technology and Global Partnerships

Shanghai Allist Pharmaceuticals (688578.SS), the developer of Furmonertinib (Ivesa®), a third-generation epidermal growth factor receptor (EGFR) targeted therapy, and ArriVent BioPharma (AVBP), which holds global rights, have released the results of the Phase 1b clinical trial (FAVOUR, NCT04858958). This study demonstrated the efficacy and safety of the drug in patients with refractory EGFR exon 20 insertion mutation non-small cell lung cancer (NSCLC), who have shown resistance to existing targeted therapies. In the lung cancer market, which has significant unmet medical needs, Furmonertinib has shown the potential to be a powerful next-generation alternative treatment.

Demonstrating Promising Efficacy Through Optimized Dose Design

The Phase 1b study evaluated the efficacy of 160mg and 240mg daily doses in treatment-naïve and previously treated patients. In the treatment-naïve group, a 240mg dose achieved a remarkable confirmed objective response rate (cORR) of 78.6% based on independent review committee (IRC) assessment. In the previously treated group, a 240mg dose showed 46.2% efficacy, and a 160mg dose showed 38.5% efficacy, demonstrating a dose-dependent therapeutic effect. The median duration of response (DOR) was also 15.2 months, supporting excellent long-term efficacy.

Excellent Blood-Brain Barrier Penetration and Good Tolerability

This study focused on blood-brain barrier (BBB) penetration to evaluate the ability to control central nervous system (CNS) metastasis, a key factor in determining the prognosis of NSCLC patients. Furmonertinib demonstrated excellent CNS anti-tumor effects, securing a differentiated clinical advantage over competing drugs. In terms of safety, frequent adverse events such as diarrhea and rash were mild (Grade 1-2), demonstrating high tolerability. The accompanying circulating tumor DNA (ctDNA) analysis also provided molecular biological evidence to demonstrate real-time therapeutic response.

Breakthrough Therapy Designation from the FDA and Accelerated Market Entry

The promising results of the FAVOUR trial led to the U.S. Food and Drug Administration (FDA) granting Breakthrough Therapy Designation on October 30, 2023. The global EGFR exon 20 mutation treatment market, valued at approximately $616 million in 2025, is expected to grow to approximately $2.841 billion by 2034, with an annual growth rate of 18.5%. Based on this data, ArriVent BioPharma is accelerating commercialization to secure market leadership by initiating the global Phase 3 trial, FURVENT.